Day: January 6, 2026

FORESIGHT ENTERPRISE VCT PLC (Company) LEI: 213800MWJNR3WZZ3ZP42Offer and Prospectus 6 January 2026 The board of the Company (Board) is pleased to announce the launch of a new offer for subscription (Offer) to raise up to £40 million through the issue of new shares (Offer Shares). The Offer will provide shareholders and new investors with a further opportunity to invest in the Company and benefit from the VCT tax reliefs available to qualifying investors. The Offer will open for applications at 9.00 a.m. on 14 January 2026 and will close for applications at 12.00 noon on 30 March 2026 (or, if earlier, as soon as the Offer is fully subscribed or otherwise at the Board’s discretion). Unless the Offer timetable is extended at the discretion of the Board, the Offer will not be open in respect of the 2026/2027 tax year. The additional funds...

Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will also participate in the following upcoming investor conference:28th Annual Needham Growth Conference – Friday, January 16, 2026Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies...

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44th Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event. 44th Annual J.P. Morgan Healthcare ConferenceDate: Wednesday, January 14, 2026Time: 8:15am PSTFormat: PresentationWebcast: Link The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the event, a replay will be available for 30 days. About ProKidney Corp.ProKidney, a pioneer in the treatment...

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, and Rockpoint, a Boston-based real estate private equity firm, today announced a joint venture for the ownership of 100 Park Avenue through SL Green’s sale of a 49% interest to Rockpoint at a gross asset valuation of $425.0 million. “We’re excited to begin our partnership with Rockpoint at 100 Park Avenue in a transaction that underscores the strength of high-quality office assets in premier locations in an improving Manhattan office market,” said Harrison Sitomer, Chief Investment Officer at SL Green. “We have known the SL Green team for a long time and look forward to partnering to maintain and enhance 100 Park’s positioning as a highly desirable midtown office destination,” said Dan Domb, a Managing Member and Chief...

Company’s bfLEAP® platform successfully identified treatment effect heterogeneity and possible early predictors of outcomes in pancreatic cancer in data to be presented at ASCO GI GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP® with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on Jan....

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) had invited the Company to present the Company’s Alzheimer’s disease clinical trial results, reflecting the Agency’s interest in the progress of Anavex’s clinical development efforts. During the Type C meeting, the FDA shared their interest and collaborative approach to Anavex’ development plans. The Company provided information related to the scientific rationale...

DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available for replay until February 14, 2026. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions....